Cipla Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/aambynlzvzpjbchpu8xqufyr.pdf

Key Takeaways


U.S. Revenue Trajectory & Pipeline

Vohra: “Well, if lenalidomide stayed at where it was now, yes, we would have got there and crossed it. But you also have to see the next 2 or 3 quarters is when we will see a compression in lena. And that will be offset by these new products that are coming up.”

Margin Outlook & Mix Shift


India Business & Chronic Mix

Vohra: “The idea of inhaled insulin is never to replace the way insulin is served in the market in India. So we don't -- by its very nature, the asset is a niche asset for people who cannot take injectable drugs or people who are hesitant to take...”

International Markets & Regional Levers


Regulatory, Tariffs & External Environment

Adukia: “we have not, in any way, got impacted by any -- and this is an evolving situation. We have to yet to see on what gets decided finally. But in our portfolio, we've not got impacted. And I think the most recent announcement doesn't really impact the generic players. In fact, it may just benefit.”

Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin23.5%–24.5% rangeFY26
U.S. quarterly revenue~$220 mnQ1 FY26
Peptide launches in U.S.3 assets (one large, two smaller); approvals expected in H2FY26
Respiratory filings4 additional assets filedNext 12–18 months
Peptide/complex generic filings10 additional assets filedNext 12–24 months
Symbicort launchGeneric version launchFY27
Advair launchCommercialized from U.S. site; launch depends on FDA priorityFY26 (early or late)
Inhaled insulin launchIndia market3–4 months
Capex~5% of revenueFY26
R&D ceilingNot to exceed 6–6.5% of revenue on a full-year basisOngoing

Key Metrics

MetricQ4 FY25
Revenue₹6,730 cr, +9% YoY
Full-year revenue₹27,548 cr, +8% YoY
EBITDA margin22.8%, +150 bps YoY
Full-year EBITDA margin25.9%, +139 bps YoY, exceeding guidance
Gross margin67.5%, +74 bps YoY
Full-year gross margin67.6%, +157 bps YoY
R&D spend₹426 cr, 6.3% of revenue
Full-year R&D spend₹1,524 cr, 5.5% of revenue
PAT₹1,222 cr, 18.2% of sales; effective tax rate 18.6%
Full-year PAT₹5,273 cr, 19.1% of sales; effective tax rate 22.4%
Net cash₹10,369 cr, after adjusting for debt of ₹438 cr including lease liabilities
FY26 EBITDA margin guidance23.5% to 24.5%
One India revenue growth8% YoY; full-year growth 7% YoY
One India chronic mix61.5% as per IQVIA MAT '25
North America quarterly revenue$221 mn; full-year revenue $934 mn
Albuterol market share18%, steady
One Africa revenue growth15% YoY in USD terms; full-year growth 12% YoY
One Africa private market secondary growth6.7% vs market growth of 4.9%
EMEU revenue growth16% YoY; full-year growth 15% YoY
U.S. Q1 FY26 revenue outlook~$220 mn
Respiratory share of global revenue~30%
Capex outlook~5% of revenue
India market growth rate range8% to 10%, down from 10% to 12% previously
South Africa normalized growth expectation4% to 5%
U.S. manufacturing split~1/3 from U.S., ~1/3 from India, ~1/3 from CMOs/rest of world